Shots:
Silence has reported topline P-II (SANRECO) trial results assessing divesiran (6mg/kg, SC, Q6W or Q12W) vs PBO in 48 phlebotomy-dependent patients with polycythemia vera (PV); P-III PV trial for Q12W dosing to initiate in H1’27
Trial met its 1EP, with significantly more PV pts responding to divesiran vs PBO (88% vs 19%). Response was…
